Latest Breaking News On - Victorg prieto - Page 1 : comparemela.com

Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50%

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.

Major pathologic response to neoadjuvant pemb

<p style="text-align:start">In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.&nbsp;These and other results of the analyses are presented as a proffered paper (Abstract LBA48) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Monday, October 23, by Sapna P. Patel, MD, chair of the SWOG melanoma committee and associate professor of melanoma medical oncology at the University of Texas MD Anderson Cancer Center.</p>

Over 50% Major Response to Pembrolizumab in Melanoma Trial

Neoadjuvant immunotherapy improves outlook in high-risk melanoma